Nimbus Therapeutics
Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.
Nimbus is a drug-discovery partner, not a product you buy, and that's the whole evaluation. The selectivity-first pipeline has current, specific proof points — SIK2 mechanistic data at IMMUNOLOGY2026, translational data headed to ECCO 2026 for IBD, and NDI-219216 completing dose escalation for MSI-H tumors in December 2025. The January 2026 Lilly obesity deal shows an active partnering motion. If you need a self-serve platform or inspectable computational models, this is the wrong shape.
Verified 19h ago · liveness 69/100 · cite: rightaichoice.com/tools/nimbus-therapeutics
- Pharma seeking highly selective small molecules for difficult oncology or immunology targets
- Biotech partners wanting computational drug design plus translational medicine in one collaborator
- Teams interested in selective SIK2 inhibitors with preclinical and translational data behind them, including IBD direction
- Organizations evaluating de-risked preclinical assets with translational evidence attached
- Teams that need public documentation of computational models and methods before engaging
- Groups wanting to screen many targets rapidly without a deep selectivity focus
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Nimbus Therapeutics if you want a self-service AI drug design platform you can log into tomorrow, or if you need published model architectures and training data before you will start a scientific conversation.
Program-level terms are negotiated rather than published, so licensing or collaboration economics surface only during direct conversations — budget time for a diligence cycle before you have numbers.
Nimbus is not a subscription purchase — it is a clinical-stage biotech that partners on small-molecule programs, with terms handled through direct contact. That puts it in a different budget category from SaaS discovery tools and makes it comparable to other structure-based design biotechs such as Relay Therapeutics rather than to per-seat platforms like Schrödinger's software offering. Fit is by therapeutic-area need and target difficulty, not by team size or seat count.
In short
Nimbus Therapeutics — Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease. Best for Pharma seeking highly selective small molecules for difficult oncology or immunology targets, Biotech partners wanting computational drug design plus translational medicine in one collaborator, Teams interested in selective SIK2 inhibitors with preclinical and translational data behind them, including IBD direction. Contact Sales pricing.
What's new in Nimbus Therapeutics
Checked yesterdayAcross the latest 5 updates: 5 news mentions.
Nimbus Therapeutics Presents New Mechanistic Data Highlighting Differentiated Biology of Selective SIK2 Inhibitors at IMMUNOLOGY2026™
Nimbus presented preclinical mechanistic data on its selective SIK2 inhibitors, emphasizing differentiated biology relevant to immunology indications.
Nimbus Therapeutics to Present Preclinical and Translational Data on Novel SIK2 Inhibitors at 21st Congress of European Crohn’s and Colitis Organisation (ECCO)
Nimbus announced it would present preclinical and translational data on novel SIK2 inhibitors at ECCO 2026, pointing toward inflammatory bowel disease as a target area.
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
Nimbus entered a research collaboration and license agreement with Lilly covering a novel oral obesity treatment, extending its metabolic disease work with the same partner behind its AMPK activator program.
Nimbus Therapeutics Announces Completion of Dose Escalation in Phase 1/2 Clinical Trial of NDI-219216, Novel WRN Inhibitor for MSI-H Tumors
Nimbus completed dose escalation in the Phase 1/2 trial of NDI-219216, its WRN inhibitor for MSI-H tumors, after initiating the first-in-human trial in April 2025.
Leadership in Drug Discovery: A Conversation with Peter Tummino, President of R&D
An interview with President of R&D Peter Tummino covering Nimbus's R&D strategy, its selectivity focus, and its approach to drug discovery.
What people actually say about Nimbus Therapeutics — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
22 mentions across 2 sources (YouTube, Bluesky) · researched Jul 26, 2026.
Average across the 2 sources that answered — each source counts once, not each post.
- +Validated drug candidates reaching Phase 3 (e.g., zasocitinib).
- +Multiple blockbuster deals with Eli Lilly and Takeda.
- +Expertise in selective allosteric modulator design.
- +Differentiated SIK2 inhibitors for immunology and inflammation.
- +Structure-based design enables tackling challenging targets.
- −No public user feedback on product usability or support.
- −YouTube search results over 80% about ASICS shoes, not the company.
- −Ties to Epstein-linked investors could raise reputational concerns.
- −Success depends heavily on partnership deals, not direct sales.
- −Pricing model (contact-based) prevents easy comparison.
Viability Score
How well maintained and how widely used is Nimbus Therapeutics? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- Computational small-molecule drug design
- Structure-based drug design
- Allosteric modulator design
- Selectivity-first target selection
- Translational medicine integrated into discovery
- Clinical development of small-molecule candidates
- Selective SIK2 inhibitors for immunology and IBD
- Preclinical and translational data generation
- Lead optimization for highly selective molecules
- Oncology pipeline including WRN inhibitor NDI-219216 for MSI-H tumors
- Metabolic disease programs including oral obesity research
- AMPK activator collaboration with Lilly
- Research collaboration and license agreement with Lilly for oral obesity (Jan 2026)
- Partnership-driven drug development and licensing model
- Research collaborations with external discovery partners such as Anagenex
About Nimbus Therapeutics
Nimbus Therapeutics is a clinical-stage biotech built around one organizing idea: selectivity. The Boston-based company applies that bar to target selection, molecule design, and the partners it signs. Its science splits into four stated pillars — target selection, drug discovery, translational medicine, and clinical development — with structure-based design and allosteric modulator design driving lead optimization.The pipeline runs across oncology, immunology, and metabolic disease. Immunology is the loudest story right now: on April 16, 2026 Nimbus presented new mechanistic data on its selective SIK2 inhibitors at IMMUNOLOGY2026, following a February 17, 2026 announcement that it would present preclinical and translational data on novel SIK2 inhibitors at ECCO 2026, pointing toward inflammatory bowel disease. On the oncology side, NDI-219216, a WRN inhibitor for MSI-H tumors, completed dose escalation in its Phase 1/2 trial on December 19, 2025, after a first-in-human start in April 2025.Partnership is the commercial engine. Nimbus expanded its Lilly relationship with a January 6, 2026 research collaboration and license agreement covering a novel oral obesity treatment — on top of an earlier AMPK activator collaboration with Lilly dating to October 2022 — and holds a multi-target collaboration with Anagenex announced December 2023. It is a drug discovery and development organization you engage as a collaborator, with terms handled by direct contact. Buyers comparing it against computational drug design platforms should expect a different shape of relationship.
Behind the Verdict
Pick Nimbus when you want a small-molecule collaborator with a strict selectivity bar and a pipeline you can actually inspect. The immunology story is the freshest: mechanistic data on selective SIK2 inhibitors landed at IMMUNOLOGY2026 in April 2026, and preclinical and translational data on novel SIK2 inhibitors was slated for ECCO 2026 in February, with inflammatory bowel disease as the apparent direction. For oncology, NDI-219216 is a WRN inhibitor for MSI-H tumors that finished dose escalation in its Phase 1/2 trial on December 19, 2025 — a de-risking milestone worth weighing.Where it bites: Nimbus does not operate like software. If your procurement process expects a vendor page with tiers, you'll be having a different conversation — terms come through direct contact, not a checkout.The partnering motion is real and current. Lilly signed a research collaboration and license agreement on January 6, 2026 for a novel oral obesity treatment, extending a relationship that already included an AMPK activator collaboration from October 2022. A multi-target collaboration with Anagenex, announced December 2023, rounds out the external discovery network. That's a track record, not a press release.The closest alternative is a computational AI drug design platform you license and run in-house. In practice those two paths solve different problems. A platform gives you throughput and control; Nimbus gives you selectivity-driven design plus translational and clinical execution attached. If you need to screen many targets rapidly without a deep selectivity focus, the platform model fits better.We'd reach for Nimbus when the target is hard,
Researching Nimbus Therapeutics? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Nimbus Therapeutics actually fits — and what changes day-one when you adopt it.
You have an inflammatory bowel disease target where selectivity is the bottleneck, and you want to evaluate Nimbus's SIK2 program data before proposing a collaboration.
Outcome: You review the mechanistic data presented at IMMUNOLOGY2026 and the translational data slated for ECCO 2026, then open a direct conversation via info@nimbustx.com about a research collaboration.
You want a de-risked preclinical-to-clinical small molecule for a genetically defined tumor population and are screening available WRN inhibitor programs.
Outcome: You assess NDI-219216, which completed dose escalation in its Phase 1/2 trial in MSI-H tumors in December 2025, and evaluate it against other WRN-directed programs in your pipeline review.
You are mapping oral obesity and AMPK activator players after seeing the January 2026 Lilly–Nimbus license and the earlier AMPK collaboration.
Outcome: You reach out to discuss a research collaboration and license structure for a novel oral metabolic program, using the Lilly deals as a reference point for how Nimbus structures partnerships.
Use Cases
- Discover highly selective small-molecule inhibitors for challenging targets like SIK2 or WRN.
- License a de-risked preclinical asset with a computational origin for faster clinical development.
- Collaborate on structure-based design of allosteric modulators for immunology indications.
- Advance a pipeline program from target selection through IND using integrated computational design and chemistry.
- Partner on metabolic disease programs, including oral obesity treatments, under a research and license agreement.
- Evaluate selective SIK2 inhibitor data for inflammatory bowel disease and other immunology indications.
Limitations
- Nimbus Therapeutics is a clinical-stage biotechnology company focused on internal small-molecule drug discovery and external partnerships, not a software product you can buy or subscribe to.
- No underlying AI models, computational tools, or training datasets are named or detailed on the public site, so teams that need to evaluate methodology before engaging will not find it here.
- Public accessibility is limited to pipeline information, science overviews, publications and presentations, and company news rather than any software or API service.
- Engagement is via direct contact (info@nimbustx.com), and program-level terms are negotiated rather than listed.
as of 2026-09-29
Verification history
We have re-verified Nimbus Therapeutics 19 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 19 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Nimbus Therapeutics's pricing actually pencils out — and where peers do it cheaper.
Nimbus is not a subscription purchase — it is a clinical-stage biotech that partners on small-molecule programs, with terms handled through direct contact. That puts it in a different budget category from SaaS discovery tools and makes it comparable to other structure-based design biotechs such as Relay Therapeutics rather than to per-seat platforms like Schrödinger's software offering. Fit is by therapeutic-area need and target difficulty, not by team size or seat count.
Setup time & first value
How long it actually takes to get something useful out of Nimbus Therapeutics — broken out by persona, not the marketing-page minute.
There is no software setup — evaluation is a scientific and business conversation. Expect days to weeks for initial contact and material exchange through info@nimbustx.com, and longer for full diligence and term negotiation on a collaboration or license. Partnering leads should budget a realistic multi-week timeline from first call to signed agreement rather than a same-day activation.
Switching to or from Nimbus Therapeutics
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From an internal-only discovery program: bring your target and selectivity challenge to Nimbus as a collaboration to add computational design and translational medicine.
- →From a software-only modeling tool: pair your existing in-house chemistry with Nimbus's integrated discovery-through-clinical model for programs that need development capability.
- →From a single-target academic collaboration: move to a structured research collaboration and license agreement with defined development and commercial stages.
- ↗To an in-house discovery platform: transition programs where your team has built sufficient structure-based design and translational capability internally.
- ↗To a CRO-led model: hand off programs where you need execution capacity rather than collaborative design and translational expertise.
- ↗To another structure-based design biotech: reassess fit if your target no longer benefits from a strict selectivity-first approach.
Resources & Guides
Tutorials & Learning
Rebecca Carazza (Nimbus Therapeutics): Leveraging ChemAxon tools to automate Nimbus’ SDFile curation
Certara - Chemaxon
Nimbus Therapeutics testimonial
Indero (formerly Innovaderm)
Biotech Series: Nimbus CEO Abbas Kazimi on Leading the Future of Precision Therapeutics
New York Stock Exchange
YouTube returned 6 videos for “Nimbus Therapeutics”, and we withheld 3: 3 did not mention Nimbus Therapeutics. Showing the 3 we can prove are about Nimbus Therapeutics.
Official links
Tools that pair well with Nimbus Therapeutics
Common stack mates teams adopt alongside Nimbus Therapeutics, with the specific reason each pairing earns its keep.
Iktos
Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.
Insilico Medicine
Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.
Flatiron Health
Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.
Featured Head-to-Head Comparisons
Alternatives to Nimbus Therapeutics
View all
Iktos
Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.
Insilico Medicine
Generative AI drug discovery suite spanning target ID, molecule design, biologics and clinical trial prediction.
Flatiron Health
Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.
Frequently Asked Questions
Categories
Best-of guides
Topics
Used Nimbus Therapeutics? Help shape our editorial sentiment research.